Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial
24 août 2022 08h00 HE
|
Enlivex Therapeutics Ltd
Sepsis Phase II protocol amendments have been cleared by regulatory authorities in Israel, Spain, and Greece. In addition to these clearances, Enlivex plans to obtain clearances for these protocol...
Enlivex Announces Second Quarter 2022 Financial Results and Provides a Business Update
22 août 2022 08h00 HE
|
Enlivex Therapeutics Ltd
Dosed first patient in Phase I/II trial evaluating Allocetra™ combined with chemotherapy in patients with peritoneal metastases arising from solid cancersReceived Israeli Ministry of Health approval...
Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
17 août 2022 08h00 HE
|
Enlivex Therapeutics Ltd
Trial builds on encouraging preclinical studies conducted in collaboration with Yale Cancer Center that showed a substantial, statistically significant survival benefit when Allocetra™ was combined...
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra™
03 août 2022 08h15 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased...
Sheba Medical Center and Enlivex Announce Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers
06 juil. 2022 08h37 HE
|
Enlivex Therapeutics Ltd
First clinical trial of Allocetra™ in patients with cancer builds upon promising preclinical studies demonstrating its broadly applicable immunotherapeutic effects in solid tumor modelsSheba Medical...
Enlivex to Present at the 2022 Jefferies Healthcare Conference
07 juin 2022 08h00 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, June 07, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in...
Enlivex Receives Israeli Ministry of Health Authorization for the Initiation of a Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers
06 juin 2022 08h00 HE
|
Enlivex Therapeutics Ltd
Trial will be the first clinical study of Allocetra™ in patients with cancer, following encouraging preclinical data presented at the International Society for Gene and Cell Therapy 2022...
Enlivex Announces New Preclinical Data in Ovarian Cancer Showing a Substantial Survival Benefit when Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology (ASCO) Annual Meeting
31 mai 2022 08h00 HE
|
Enlivex Therapeutics Ltd
Stand-alone therapy with PD1 checkpoint inhibitors has shown limited efficacy against ovarian cancer, with response rates in prior clincical trials ranging from 7-15%. This contributes to poor patient...
Enlivex Awarded Its Third Non-Dilutive Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis Patients
25 mai 2022 08h00 HE
|
Enlivex Therapeutics Ltd
Grant provides $1.2 million in non-dilutive funding for 2022 sepsis clinical trial expensesTo date, Enlivex has received a total of $7.8 million in non-dilutive grants from the Israel Innovation...
Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman
23 mai 2022 08h00 HE
|
Enlivex Therapeutics Ltd
Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of...